QUICK ANSWER
The nuclear dot pattern is a specific fluorescence pattern seen on a positive ANA by IFA test. Discrete bright dots appear within cell nuclei under the microscope. There are two main types — and distinguishing between them matters clinically.
| Sub-type | ICAP code | Dots per nucleus | Primary association |
|---|---|---|---|
| Multiple nuclear dots | AC-6 | Classically ~6–20 per cell | Primary biliary cholangitis (PBC); anti-Sp100 and anti-Sp140 antibodies |
| Few nuclear dots | AC-7 | Classically ~1–6 per cell | Low positive predictive value; p80-coilin / SMN complex; often incidental |
Common questions at a glance:
| Question | Short answer |
|---|---|
| What does nuclear dot pattern mean on ANA? | Discrete bright dots within cell nuclei — a specific ANA fluorescence pattern |
| What does "multiple nuclear dots" mean? | ~6–20 dots per nucleus (AC-6); most commonly associated with primary biliary cholangitis |
| What does "few nuclear dots" mean? | ~1–6 dots per nucleus (AC-7); low positive predictive value; often incidental |
| What does "discrete nuclear dots" mean? | Same as nuclear dot pattern — "discrete" describes the sharply defined appearance of the dots |
| What does "nuclear dot pattern high" mean? | A positive nuclear dot pattern with a high titer — the number refers to antibody concentration, not dot count |
| What diseases are associated with nuclear dot pattern? | AC-6: primarily PBC; AC-7: low disease specificity |
WHAT IS THE NUCLEAR DOT PATTERN?
The nuclear dot pattern is one of the recognized ANA fluorescence patterns classified by the International Consensus on ANA Patterns (ICAP). When a blood sample is tested for antinuclear antibodies by indirect fluorescent antibody (IFA) method, the serum is applied to HEp-2 cells on a glass slide. If antinuclear antibodies are present, they bind to specific structures inside the cell nucleus, producing a fluorescence pattern visible under a fluorescent microscope.
The nuclear dot pattern appears as a small number of sharply defined (discrete) bright fluorescent dots located within the nucleus — distinct from the diffuse or granular staining of other ANA patterns. The dots correspond to specific nuclear bodies — compact protein structures inside the nucleus that serve regulatory functions in gene expression, antiviral response, and protein processing.
Why the nuclear dot pattern is distinct from other ANA patterns:
| Pattern | Appearance under microscope | Key distinction from nuclear dots |
|---|---|---|
| Nuclear dot (AC-6/AC-7) | Small number of discrete bright dots within the nucleus | Dots are few and sharply defined |
| Homogeneous | Uniform staining across the entire nucleus | Diffuse — no distinct dots |
| Speckled | Fine or coarse granular staining throughout nucleus | More numerous and less distinct than nuclear dots |
| Nucleolar | Staining concentrated in the nucleolus | Located in nucleolus, not in nuclear body dots |
| Centromere (AC-3) | Many dots at centromere/kinetochore positions — ICAP describes ~40–80 per cell | Many more dots than nuclear dot pattern |
FEW NUCLEAR DOTS VS MULTIPLE NUCLEAR DOTS — THE KEY DISTINCTION
The ICAP nomenclature divides the nuclear dot pattern into two distinct sub-types. The distinction has significant clinical relevance.
AC-6: Multiple Nuclear Dots
| Feature | Details |
|---|---|
| Appearance | Classically ~6–20 discrete dots per cell (ICAP); the lab's pattern call matters more than counting yourself |
| ICAP code | AC-6 |
| Nuclear structure targeted | PML nuclear bodies (also called ND10 bodies) — protein complexes involved in antiviral response, DNA repair, and gene regulation |
| Associated antibodies | Anti-Sp100 (most common, PBC context), anti-Sp140 (PBC context), anti-NXP-2/MJ (dermatomyositis context) |
| Primary clinical association | Primary biliary cholangitis (PBC) — the strongest and most consistent disease association for anti-Sp100/Sp140 |
| Other associations | Autoimmune hepatitis, PBC/AIH overlap syndrome, dermatomyositis (when anti-NXP-2 is the responsible antibody) |
| Clinical significance | More diagnostically meaningful than AC-7; anti-Sp100 and anti-Sp140 are clinically validated PBC markers |
AC-7: Few Nuclear Dots
| Feature | Details |
|---|---|
| Appearance | Classically ~1–6 discrete dots per cell (ICAP) |
| ICAP code | AC-7 |
| Associated antigens | p80-coilin and SMN complex proteins |
| Nuclear structure targeted | Cajal bodies (coiled bodies) and nuclear gems — structures involved in RNA processing |
| Disease association | Low positive predictive value for any specific disease (ICAP) |
| Testing limitation | Specific commercial immunoassays for p80-coilin/SMN complex antibodies are not routinely available |
| Clinical significance | Usually interpreted with symptoms, titer, and other findings; substantially less specific than AC-6 |
Important: The split between AC-6 and AC-7 is based on the laboratory's pattern call and any ICAP code provided — not on counting dots yourself. Because the ranges overlap at approximately 6 dots per cell, the lab's reported sub-type or ICAP code is the authoritative classification.
WHAT DOES "DISCRETE NUCLEAR DOTS" MEAN?
"Discrete nuclear dots" is the descriptive term laboratories use to report the nuclear dot ANA pattern. "Discrete" refers to the sharply defined, individually distinct appearance of the dots — each dot is separate and clearly bounded, unlike the more diffuse or granular staining of other ANA patterns.
When your report says "Discrete Nuclear Dots," it is describing the same finding as "nuclear dot pattern." The word "discrete" is a morphological descriptor telling you the dots are well-defined and individually distinguishable — it does not mean the finding is separate from your ANA result or indicate a specific severity level.
WHAT DOES "NUCLEAR DOT PATTERN HIGH" MEAN?
When a report states "nuclear dot pattern high" or shows the pattern alongside a high titer, the "high" refers to the ANA titer — the dilution at which antibodies remain detectable — not to the number of dots or the pattern's appearance.
| Titer with nuclear dot pattern | Clinical interpretation |
|---|---|
| 1:40 | Low positive — may be incidental; clinical correlation required |
| 1:80 | Low positive — requires clinical context; common even in healthy individuals |
| 1:160 | More likely to be clinically meaningful than very low titers; consider sub-type, symptoms, liver enzymes, and specific antibody testing |
| 1:320 | Higher positive — more concerning when AC-6 is present with cholestatic liver enzymes or PBC-specific antibodies |
| 1:640 and above | High titer — more clinically significant, especially with AC-6 and cholestatic pattern; titer alone does not diagnose disease |
For nuclear dot pattern, the most important interpretation variables are: AC-6 vs AC-7, titer, ALP/GGT pattern, AMA status, anti-Sp100/Sp140/gp210 results, and symptoms.
PRIMARY CLINICAL ASSOCIATION — PRIMARY BILIARY CHOLANGITIS (PBC)
The multiple nuclear dots pattern (AC-6) is one of the ANA patterns most specifically associated with primary biliary cholangitis (PBC) — a chronic autoimmune liver disease affecting the small bile ducts. A positive AC-6 pattern is a meaningful clue that should prompt PBC evaluation, especially when alkaline phosphatase or GGT is elevated, AMA is positive or unavailable, or symptoms such as itching and fatigue are present. The pattern alone does not diagnose PBC.
What is PBC? Primary biliary cholangitis (formerly called primary biliary cirrhosis) is an autoimmune condition in which the immune system attacks the small bile ducts inside the liver, causing progressive inflammation and scarring. It predominantly affects middle-aged women. Common symptoms include fatigue and itching (pruritus). Elevated alkaline phosphatase (ALP) and GGT are the characteristic biochemical findings. If diagnosed, first-line treatment is ursodeoxycholic acid (UDCA), and response is monitored with liver enzymes over time. Treatment is considered only if PBC is clinically diagnosed — a nuclear dot pattern alone is not a reason to start UDCA.
ANA patterns in PBC:
| ANA pattern | Antibody | Prevalence in PBC | Clinical significance |
|---|---|---|---|
| Multiple nuclear dots (AC-6) | Anti-Sp100, anti-Sp140 | ~25–30% of PBC patients | Highly specific for PBC; particularly useful when AMA is negative |
| Nuclear envelope/rim | Anti-gp210, anti-p62 | ~20–25% of PBC patients | Also PBC-associated; anti-gp210 may indicate more progressive disease |
| Speckled | Various | Common but less specific | Less diagnostically specific for PBC |
PBC evaluation components when nuclear dots are found:
| Component | Why it matters |
|---|---|
| Alkaline phosphatase (ALP) | Key cholestatic liver enzyme; persistent elevation is central to PBC evaluation |
| GGT | Supports cholestatic liver pattern when ALP is elevated |
| AMA / AMA-M2 | Primary PBC antibody; positive in most PBC cases |
| Anti-Sp100 / anti-Sp140 | PBC-specific nuclear body antibodies; especially useful when AMA is negative |
| Anti-gp210 | PBC-specific nuclear envelope antibody; may suggest more aggressive disease course |
| Bilirubin, albumin, platelets, INR | Help assess liver function and disease severity |
| Liver ultrasound | Helps exclude biliary obstruction or other structural liver disease |
| Hepatology referral | Appropriate when nuclear dots occur with cholestatic liver enzymes or PBC-specific antibodies |
Anti-Sp100: Anti-Sp100 targets the Sp100 nuclear antigen — a component of PML nuclear bodies. It is highly specific for PBC and is the antibody most commonly responsible for the AC-6 pattern in a liver disease context. Anti-Sp140, sometimes discussed in the broader PML nuclear body antibody context, may be included in some liver autoantibody profiles; in routine PBC evaluation, anti-Sp100 and anti-gp210 are more commonly emphasized clinically, especially when AMA is negative.
WHY NUCLEAR DOTS MATTER WHEN AMA IS NEGATIVE
Most PBC patients test positive for anti-mitochondrial antibody (AMA) — the primary PBC serological marker. However, a minority of PBC patients are AMA-negative. In that situation, PBC-specific ANA patterns and antibodies become especially important for diagnosis.
According to AASLD and EASL PBC guidelines, PBC can be established in AMA-negative patients when cholestatic liver enzyme elevation is present alongside PBC-specific ANA immunofluorescence patterns — such as the multiple nuclear dots pattern — or PBC-specific antibodies including anti-Sp100 and anti-gp210.
This is why a multiple nuclear dots (AC-6) finding should always be interpreted alongside ALP, GGT, AMA, anti-Sp100, anti-Sp140, anti-gp210, and symptoms such as itching or fatigue — particularly when AMA is unavailable or negative.
What if AMA or anti-Sp100 is positive but ALP and GGT are completely normal? A positive PBC-associated antibody without cholestatic liver enzyme elevation does not automatically diagnose PBC. In this situation, clinicians usually monitor liver enzymes over time and interpret the result with symptoms, imaging, and antibody profile. Current guidelines note that AMA alone without cholestatic biochemistry is not sufficient to diagnose PBC.
NUCLEAR DOT PATTERN VS NUCLEAR ENVELOPE/RIM PATTERN — A COMMON PBC CONFUSION
Both multiple nuclear dots and nuclear envelope/rim are PBC-associated ANA patterns, but they are different findings produced by different antibodies:
| Pattern | ICAP code | Appearance | PBC antibody context |
|---|---|---|---|
| Multiple nuclear dots | AC-6 | Multiple discrete dots within the nucleus | Anti-Sp100, anti-Sp140 — PBC-associated |
| Nuclear envelope/rim | AC-11 and related | Staining around the border of the nucleus | Anti-gp210, anti-p62 — PBC-associated; anti-gp210 may indicate more aggressive disease course |
| Centromere | AC-3 | Many dots (~40–80 per cell) at kinetochore positions | Anti-centromere — limited systemic sclerosis/CREST, not PBC |
Both nuclear dots (AC-6) and nuclear envelope/rim can be seen in PBC patients, and some patients may have both patterns. Neither individually diagnoses PBC — both require clinical and biochemical correlation.
WHAT DOES NUCLEAR DOT PATTERN MEAN FOR OTHER CONDITIONS?
While PBC is the primary association for AC-6, nuclear dot patterns can also be seen in:
| Condition | Notes |
|---|---|
| Autoimmune hepatitis (AIH) | Nuclear dot pattern may appear in AIH/PBC overlap syndrome |
| PBC/AIH overlap syndrome | One of the most clinically important contexts — both patterns and specific antibodies guide management |
| Dermatomyositis / inflammatory myopathy | When anti-NXP-2/MJ is the responsible antibody rather than anti-Sp100/Sp140 — different clinical context entirely |
| Sjögren's syndrome | Occasional association; usually accompanied by anti-SSA/Ro antibodies |
| Healthy individuals | AC-7 (few nuclear dots) may be seen as an incidental finding, particularly at low titer; ICAP notes AC-7 has low positive predictive value |
Anti-NXP-2/MJ and dermatomyositis: Anti-NXP-2/MJ is a myositis-associated antibody that can produce a multiple nuclear dots pattern on HEp-2 cells. It is most relevant when the patient has dermatomyositis or inflammatory myopathy features such as proximal muscle weakness, elevated CK or aldolase, characteristic rash (heliotrope rash, Gottron's papules), or dysphagia. In adults with confirmed inflammatory myopathy, anti-NXP-2 has been reported in association with malignancy risk, but a nuclear dot pattern alone does not indicate cancer — clinical context and specific antibody testing determine whether NXP-2 follow-up is appropriate.
SELECTED ICAP NUCLEAR PATTERN CODES RELEVANT TO NUCLEAR DOTS
Some laboratory reports use ICAP (International Consensus on ANA Patterns) AC-code nomenclature. Here are the codes most relevant when interpreting nuclear dot results:
| ICAP code | Pattern name | Description |
|---|---|---|
| AC-1 | Homogeneous | Uniform nuclear staining |
| AC-2, AC-3, AC-4, AC-5 | Speckled variants | Fine or coarse granular nuclear staining |
| AC-6 | Multiple nuclear dots | ~6–20 discrete nuclear dots per cell; PML nuclear bodies |
| AC-7 | Few nuclear dots | ~1–6 discrete nuclear dots per cell; Cajal bodies |
| AC-8, AC-9, AC-10 | Nucleolar patterns | Staining in nucleolus |
| AC-11 | Nuclear envelope/rim | Staining at nuclear border; PBC-associated |
| AC-3 | Centromere | ~40–80 dots at kinetochore positions; limited systemic sclerosis |
| AC-13 | PCNA | Proliferating cell nuclear antigen pattern |
| AC-29 | Dense fine speckled (DFS70) | DFS70/LEDGFp75 antibody |
Note: ICAP also lists additional pattern codes (AC-30, AC-31, and others) for less common patterns. If you see an AC code not listed here, refer to the ICAP website (anapatterns.org) for the full current classification.
SPECIFIC ANTIBODY FOLLOW-UP AFTER NUCLEAR DOT PATTERN
A positive nuclear dot pattern on ANA by IFA typically prompts follow-up with specific antibody tests:
| Follow-up test | Why ordered after nuclear dot pattern |
|---|---|
| Anti-Sp100 | Most common AC-6 antibody in PBC context; highly specific for PBC |
| Anti-Sp140 | Related PBC-associated PML nuclear body antigen; included in some liver autoantibody profiles |
| AMA / AMA-M2 | Primary PBC antibody; ordered to complete PBC workup |
| Anti-gp210 | PBC-specific nuclear envelope antibody; not a nuclear dot antibody, but ordered in PBC workup |
| ALP, GGT, bilirubin, ALT/AST | Biochemical liver context to determine if cholestatic pattern is present |
| Anti-NXP-2/MJ | Consider only if dermatomyositis or inflammatory myopathy features are present (muscle weakness, elevated CK) |
| Anti-coilin / SMN complex | AC-7/few nuclear dots context; specific commercial tests not routinely available |
WHEN SHOULD I WORRY ABOUT A NUCLEAR DOT PATTERN?
| Situation | Concern level | Suggested follow-up |
|---|---|---|
| AC-7 few nuclear dots + low titer + no symptoms | Low | Clinical correlation; usually not urgent; ICAP notes low positive predictive value |
| AC-6 multiple nuclear dots + normal ALP/GGT + no symptoms | Low-Moderate | Check AMA/AMA-M2, anti-Sp100/Sp140/gp210; monitor liver enzymes over time |
| AC-6 + elevated ALP or GGT | Moderate-High | PBC workup; hepatology referral |
| AC-6 + positive AMA or anti-Sp100 | Moderate-High | PBC evaluation; hepatology referral |
| AC-6 + elevated ALP/GGT + AMA negative | Moderate-High | Anti-Sp100, anti-Sp140, anti-gp210 testing; hepatology referral — this is a key scenario for AMA-negative PBC |
| Nuclear dots + muscle weakness + elevated CK/aldolase | Moderate-High | Myositis evaluation; anti-NXP-2/MJ testing; rheumatology referral |
| Nuclear dots + jaundice, severe itching, dark urine, pale stools | Higher urgency | Prompt medical evaluation |
MOST COMMON CLINICAL SCENARIOS
| Pattern | Most likely interpretation | Recommended next step |
|---|---|---|
| AC-6 + fatigue + elevated ALP | Probable PBC — classic presentation | Anti-Sp100, AMA, GGT, bilirubin; hepatology referral |
| AC-6 + normal ALP/GGT + no symptoms | Possible early/incidental finding; PBC not diagnosed from pattern alone | Check AMA/AMA-M2 and anti-Sp100/Sp140/gp210; repeat liver enzymes with clinician guidance |
| AC-6 + elevated ALP/GGT + positive anti-Sp100 or AMA | Strong PBC evaluation pattern | Hepatology referral |
| AC-6 + elevated ALP/GGT + AMA negative + anti-Sp100 positive | AMA-negative PBC pattern | Hepatology referral; UDCA evaluation |
| AC-7 + no symptoms + low titer | Likely incidental; low clinical significance | Clinical correlation; avoid overdiagnosis; no urgent action needed |
| AC-7 + autoimmune symptoms | Requires clinical context | Specific antibody testing; evaluate with other clinical findings |
| Nuclear dot pattern + high titer (1:320+) + liver symptoms | Clinically significant | Full PBC workup; hepatology evaluation |
| Nuclear dot pattern (AC-6) + positive anti-NXP-2 + muscle weakness | Dermatomyositis context | Myositis evaluation; muscle enzymes; rheumatology referral |
| Nuclear dot pattern + ANA 12 Plus Profile ordered | ANA 12 Plus Profile includes broad autoimmune markers but does not include PBC-specific anti-Sp100, anti-Sp140, anti-gp210, or AMA | If AC-6 is reported, order liver-focused follow-up separately: ALP, GGT, AMA/AMA-M2, anti-Sp100/Sp140, anti-gp210; hepatology evaluation if liver markers are abnormal |
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →Frequently Asked Questions
What does nuclear dot pattern mean on an ANA test?
What does "discrete nuclear dots" mean?
What does "few nuclear dots" mean on an ANA test?
What does "multiple nuclear dots" mean on an ANA test?
What diseases are associated with the nuclear dot ANA pattern?
What does "nuclear dot pattern high" mean?
Is a nuclear dot pattern on ANA serious?
What is anti-Sp100 and why is it important?
What is the difference between nuclear dot pattern and centromere pattern on ANA?
Can a nuclear dot pattern be seen in healthy people?
Does a nuclear dot pattern mean I have PBC?
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.
-
International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results
-
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases
-
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
-
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies
-
Autoimmune liver serology: current diagnostic and clinical challenges
-
AC-6 Multiple Nuclear Dots.
-
AC-7 Few Nuclear Dots.
-
PBC2